±â»ç (Àüü 33°Ç) Á¦¸ñº¸±âÁ¦¸ñ+³»¿ë
[ÇмúÇà»ç] NSAID¿¡ ÀÇÇÑ À§º´Áõ ¹× À庴ÁõÀÇ ¹ß»ý ±âÀü°ú Ä¡·á Àü·«
Session 1ÁÂÀå : ÀÌ¿ëÂù ±³¼ö | ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¼¼ºê¶õ½ºº´¿ø¿¬ÀÚ ¹× ÁÖÁ¦ : Treatment of NSAIDs and Aspirin induced Gastropathy ; ¼­¿ï´ëÇб³º´¿ø ±è»ó±Õ ±³¼öSession 2ÁÂÀå : Çѵ¿¼ö ±³¼ö |
¸ÞµðÄ®·³   2017-09-25
[ÇмúÇà»ç] Cardiology Expert Meeting
ÁÂÀå: Á¤¿í¼º ±³¼ö(¼­¿ï¼º¸ðº´¿ø)¿¬ÀÚ ¹× ÁÖÁ¦1. Anticoagulation for Stroke Prevention in Atrial Fibrillation: Rocket AF sub-group analysis with real world data_
¸ÞµðÄ®·³   2016-07-08
[ÇмúÇà»ç] GERD ¹× ½Äµµ À̿ϺҴÉÁõ Ä¡·á¿¡ °üÇÑ ÃֽŠÁö°ß
ÁÂÀå: ¼³»ó¿µ ±³¼ö (ºÎ»ê¹éº´¿ø)½Äµµ¿¡¼­´Â ´Ù¾çÇÑ ÁúȯµéÀÌ ¹ß»ýÇÒ ¼ö Àִµ¥ ±× Áß °¡Àå ´ëÇ¥ÀûÀÎ ÁúȯÀº GERD¶ó°í ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÃÖ±Ù ±× ºÐ·ù ¹× Ä¡·á¿¡ ÀÖ¾î Áö¼ÓÀûÀÎ ¾÷µ¥ÀÌÆ®°¡ ÀÌ·ç¾îÁö°í ÀÖ´Â ½Äµµ À̿ϺҴÉÁõ(achalasia)À» ´ë»óÀ¸·Î º´
¸ÞµðÄ®·³   2016-06-21
[ÇмúÇà»ç] Differentiated CCB - CODIPINE Symposium
ÁÂÀå : ±è¾ç¿í ±³¼ö/ ÇØ¿î´ë¹éº´¿ø ½ÅÀå³»°úBenidipineÀº L, N, TŸÀÔ Ä®½· ä³ÎÀ» ¸ðµÎ Â÷´ÜÇÏ´Â À¯ÀÏÇÑ CCB Á¦Á¦À̸ç, »ç±¸Ã¼³»¾ÐÀ» Áõ°¡½ÃÅ°Áö ¾Ê¾Æ ½ÅÀ庸ȣ È¿°ú¸¦ ±â´ëÇÒ ¼ö ÀÖ°í, ÇöÀç ³Î¸® »ç¿ëµÇ°í ÀÖ´Â CCBÀÎ Amlodipine
¸ÞµðÄ®·³   2016-05-30
[ÇмúÇà»ç] ³úÁ¹ÁßÀÇ ¿¹¹æ°ú Ä¡·á¿¡¼­ ASA/ERDPÀÇ ÀÓ»óÀû À¯¿ë¼º Æò°¡ ¹× Àü¸Á
Opening³úÁ¹ÁßÀÇ Àç¹ßÀ» ¸·±â À§ÇØ ´Ù¾çÇÑ Ç×Ç÷¼ÒÆÇÁ¦°¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. °¢°¢ÀÇ ¾à¹°µéÀº ¼­·Î ´Ù¸¥ ±âÀüÀ¸·Î Ç÷¼ÒÆÇ ÀÀÁýÀ» ¾ïÁ¦Çϴµ¥, ÀÌ Áß aspirin°ú dipyridamole ¼­¹æÇü Á¦Á¦ÀÇ º¹ÇÕÁ¦ÀÎ ASA/ERDP´Â Ç÷¼ÒÆÇ ÀÀÁý°ú °ü·ÃµÈ
¸ÞµðÄ®·³   2016-02-11
[ÇмúÇà»ç] °Ç¼º¾È Ä¡·á¿Í CME ¿¹¹æÀÇ ÃÖ½ÅÁö°ß
¾È°ú Áúȯ Áß °Ç¼º¾ÈÀº ´«¹°¸· ºÒ¾ÈÁ¤°ú ¿°Áõ¿¡ ÀÇÇØ ¹ß»ýÇÏ´Â ÁúȯÀ¸·Î ¹æÄ¡ ½Ã ½Å°æ ¼Õ»ó±îÁö ÀÏÀ¸Å°°Ô µÇ´Â ÁúȯÀÔ´Ï´Ù. °ú°Å °Ç¼º¾È Ä¡·á¸¦ À§ÇØ ¿°Áõ ¾ïÁ¦ È¿°ú°¡ ÀÖ´Â cyclosporineÀ» Åõ¿©ÇÏ¿´´Âµ¥, ÃÖ±Ù ±¹³»¿¡¼­ Á¡¾È°¨À» Çâ»ó ½ÃŲ cyclo
¾È¼ºÁ¾ ±âÀÚ   2015-11-02
[ÇмúÇà»ç] ·ù¸¶Æ¼½º°üÀý¿° ȯÀÚ¿¡¼­ ¼Ò¿°ÁøÅëÁ¦¿Í methotrexateÀÇ º´¿ëó¹æ½Ã ¹®Á¦Á¡ ¹× ÇØ°á¹æ¾È
MeloxicamÀÇ ¾àµ¿ÇÐ(PK) µ¥ÀÌÅÍ´Â ´Ù¸¥ NSAIDs¿Í À¯»çÇϸç, 50%´Â ¼Òº¯À¸·Î, 50%´Â ´ëº¯À¸·Î ¹è¼³µÇ°í, ¹Ý°¨±â´Â 20½Ã°£À¸·Î Á¶»çµÇ¾ú´Ù. 15mg ´Üȸ Åõ¿© ÈÄ È°¾×(synovial fluid) ³» Ä¡·á³óµµ, Áï COX-2ÀÇ 50%
¸ÞµðÄ®·³   2015-07-02
[ÇмúÇà»ç] Lipid Management for diabetic patients
¿ì¸®³ª¶ó´Â ´ç´¢º´ ȯÀÚÀÇ 79.6%°¡ ÀÌ»óÁöÁúÇ÷ÁõÀ» µ¿¹ÝÇÏ°í ÀÖ´Ù. ±×·¯³ª ÀÌ·¯ÇÑ ³ôÀº À¯º´·ü¿¡µµ ºÒ±¸ÇÏ°í ÀÌ»óÁöÁúÇ÷ÁõÀÇ Ä¡·áÀ²Àº 24%, Ä¡·á¿¡ µû¸¥ Á¶Àý·üÀº 18%¿¡µµ ¹ÌÄ¡Áö ¸øÇÏ´Â ½ÇÁ¤ÀÌ´Ù. ƯÈ÷ ´ç´¢º´¼º ÀÌ»óÁöÁúÇ÷ÁõÀº sdLDL(small de
¸ÞµðÄ®·³   2015-07-02
[ÇмúÇà»ç] The Role of Glycosaminoglycans in Vascular Disease
GCX(glycocalyx)´Â ÁÖ·Î ³»ÇǼ¼Æ÷¸·ÀÇ Ç¥ÇÇÃþÀÇ ±¸Á¶¹°À» ¸»ÇÏ´Â °ÍÀ¸·Î, À̸§¿¡¼­ ¾Ë ¼ö ÀÖµíÀÌ ¸·°áÇÕ¼º proteoglycans¿¡ ¿¬°áµÈ GAG(glycosaminoglycan)À¸·Î ÀÌ·ç¾îÁ³´Ù. GAG Á¾·ù¿¡´Â HS(heparan sulfa
¸ÞµðÄ®·³   2015-07-02
[ÇмúÇà»ç] Women¡¯s cardiovascular management: Hypertension and CVD prevention
ÀӽźÎÀÇ ¾à 10%´Â Á¤»óº¸´Ù Ç÷¾ÐÀÌ ³ôÀ¸¸ç, ÀÌ´Â ÅÂ¾Æ¿Í ¸ðü¿¡°Ô ¸ðµÎ ÀÌȯµÈ´Ù. Áï, žÆÀÇ 12%´Â Á¶»êÀ¸·Î, ¸ðü¿¡°Ô´Â ³úÁ¹Áß, ¿ïÇ÷¼º ½ÉºÎÀü(congestive heart failure, CHF), ½Å±â´É ¼Õ»óÀÇ À§ÇèÀÌ ÀÖÀ¸¸ç, ±×·Î ÀÎÇÑ ¸ð
¸ÞµðÄ®·³   2015-07-02
[ÇмúÇà»ç] An Effective Management for Hypertension
FOCUS Study´Â ±¹³»¿¡¼­ ÁøÇàÇÑ ¿¬±¸·Î, °íÇ÷¾Ð ȯÀÚ 370¸í´ë»óÀ¸·Î, nifedipine°ú valsartan Àú¿ë·® º´¿ë¿ä¹ý°ú µÎ ¾àÁ¦ °¢°¢ÀÇ °í¿ë·® ´ÜÀÏ¿ä¹ýÀÌ Á᫐ Ç÷¿ªÇп¡ ¹ÌÄ¡´Â ¿µÇâÀ» ºñ±³ÇÑ ÀÓ»óÀÌ´Ù. °íÇ÷¾Ð ÃøÁ¤ÀÇ ¿©·¯ ¹æ¹ý Áß Áß½ÉÇ÷
¾È¼ºÁ¾ ±âÀÚ   2015-05-28
[ÇмúÇà»ç] The essential therapy for the prevention of Cardiovascular Disease
Áö±Ý±îÁö ÀÌ·ç¾îÁø aspirin ¿¬±¸ °á°ú¿Í ÇöÀç »ç¿ëÇöȲ¿¡ ´ëÇØ ¸®ºä Çغ¸°Ú´Ù. AspirinÀº 1897³â Felix HoffmannÀÌ ÇÕ¼º¿¡ ¼º°øÇÏ¿´À¸¸ç, Áö±Ý±îÁö 100³â ³Ñ°Ô ÀǾàÇ°À¸·Î »ç¿ëµÇ°í ÀÖ´Ù. À̹ø ½Ã°£¿¡´Â ½ÉÇ÷°ü Áúȯ ÀÌÂ÷ ¿¹¹æ¿¡ a
¸ÞµðÄ®·³   2015-03-12
[ÇмúÇà»ç] Recent concept of treatment for lumbar degenerative diseases
Á¤Çü¿Ü°ú¿¡¼­´Â ´ë°³ X-ray ¼Ò°ßÀ» ±Ù°Å·Î ¼ö¼ú °á°ú¸¦ Æò°¡ÇÏÁö¸¸, ÀÌ·¯ÇÑ ¿µ»ó ¼Ò°ß°ú ÀÓ»ó °á°ú ¹× Ä¡·á¿¡ ´ëÇÑ È¯ÀÚ ¸¸Á·µµ°¡ ¼­·Î ÀÏÄ¡ÇÏÁö ¾ÊÀº °æ¿ìµµ ²Ï ¸¹´Ù. ÀÌ °æ¿ì ¼ö¼úÀ» Çß´ø ¿Ü°úÀǵéÀº ´ë°³ ȯÀÚ°¡ È£¼ÒÇÏ´Â ³»¿ëº¸´Ù ¿µ»ó °Ë»ç °á°ú¿¡ ÃÊ
¸ÞµðÄ®·³   2015-02-16
[ÇмúÇà»ç] The risk management of CVD with low dose Aspirin
¿¾³¯ºÎÅÍ ¹öµå³ª¹«´Â ÅëÁõÀÌ ÀÖÀ» ¶§ ¾àÀ¸·Î »ç¿ëµÇ¾úÀ¸¸ç, 1800³â´ë Á߹ݿ¡ À̸£·¯¼­´Â ÀÌ ¹öµå³ª¹«¿¡¼­ ÃßÃâÇÑ »ì¸®½Ç»ê(salicylic acid)¿¡ ÁøÅëÈ¿°ú°¡ ÀÖ´Â °ÍÀ¸·Î ¹àÇôÁ³´Ù. ÀÌÈÄ 1899³â ¹ÙÀÌ¿¤¿¡¼­ ÀÏÇÏ´ø Felix HoffmanÀÌ ¹öµå³ª
¸ÞµðÄ®·³   2015-01-30
[ÇмúÇà»ç] Recent Advances in Platelet Aggregation Inhibitors
Ç÷¼ÒÆÇ È°¼ºÈ­ °úÁ¤Àº ¿©·¯ °æ·Î ¹× ÀÎÀÚ°¡ ÀÛ¿ëÇϱ⠶§¹®¿¡ ¸Å¿ì º¹ÀâÇÏÁö¸¸, ´Ü¼øÈ÷ µµ½ÄÈ­Çϸé Ç÷°üº®ÀÌ ¼Õ»óÀ» ÀÔÀ¸¸é, È°¼ºÈ­µÈ Ç÷¼ÒÆÇÀÌ µ¿¿ø ¹× ºÎÂøµÇ¸é¼­, ÁöÇ÷µÇ´Â °ÍÀ¸·Î Á¤¸®ÇÒ ¼ö ÀÖ´Ù. Ç÷¼ÒÆÇ È°¼ºÈ­´Â Å©°Ô ADP, Æ®·Òºó(thrombin),
¸ÞµðÄ®·³   2015-01-29
[ÇмúÇà»ç] Lipid Management for diabetic patients
Áö³­ 2013³â 11¿ù ¹ßÇ¥µÈ ACC/AHA °¡À̵å¶óÀο¡¼­´Â ´ÙÀ½ÀÇ 4°³ ȯÀÚ±º¿¡°Ô statin Ä¡·á¸¦ ±ÇÇÏ°í ÀÖ´Ù. ù°, Class II-IV¿¡ ÇØ´çÇÏ´Â ½ÉºÎÀüÀ» µ¿¹ÝÇÏÁö ¾ÊÀ¸¸ç Åõ¼®Ä¡·á°¡ ÇÊ¿äÄ¡ ¾ÊÀº Á׻󵿸ưæÈ­¼º½ÉÇ÷°üÁúȯ(atherosclero
¸ÞµðÄ®·³   2015-01-07
[ÇмúÇà»ç] Recent Advances in Platelet Aggregation Inhibitors
Ç÷¼ÒÆÇ Çü¼º ¹× ÀÀ°í °úÁ¤¿¡¼­´Â Ç÷¼ÒÆÇ È°¼ºÈ­¿Í ÇÔ²² Æ®·Òºó(thrombin)ÀÇ ÀÛ¿ëÀ¸·Î ÁöÇ÷ÀÌ ÀÌ·ç¾îÁö¸é¼­ Ç÷±«(clot)°¡ Çü¼ºµÇ±â ¶§¹®¿¡ ³úÁ¹ÁßÀ» ºñ·ÔÇÑ ½É³úÇ÷°üÁúȯÀÇ Ä¡·á¿Í ¿¹¹æ¿¡´Â ÁÖ·Î ÀÌ ´Ü°è¸¦ Â÷´ÜÇÏ´Â ¾àÁ¦µéÀÌ ÁÖ·Î »ç¿ëµÈ´Ù. ƯÈ÷ P2Y
¸ÞµðÄ®·³   2015-01-07
[ÇмúÇà»ç] HTN Management: FOCUS study
Ç÷¾Ð ÃøÁ¤ÀÇ ±â¿ø ¹× Áß½ÉÇ÷¾ÐÀÇ Á߿伺¡ß Ç÷¾ÐÀÇ ÀÓ»óÀû ÀÇ¹Ì : ÀϹÝÀûÀ¸·Î »ó¿Ï¿¡¼­ ÃøÁ¤ÇÑ Ç÷¾ÐÀ» ±Ù°Å·Î °íÇ÷¾Ð Ä¡·á¸¦ ÇÏ¸é µÈ´Ù°í »ý°¢ÇÏÁö¸¸, ´Ü¼øÈ÷ »ó¿Ï¿¡¼­ ÃøÁ¤ÇÑ Ç÷¾Ð¸¸ ±âÁØÀ¸·Î ÇÏ´Â °Íº¸´Ù Áß½ÉÇ÷¾Ð, pressure wave form¿¡¼­ ÆÄ»ýÇÏ
¸ÞµðÄ®·³   2015-01-06
[ÇмúÇà»ç] ´ëÇѾȰúÇÐȸ Çмú´ëȸ Luncheon symposium
Dr. DAVID DIAZ VALLE / Hospital Clinico San Universitario Carlos(½ºÆäÀθ¶µå¸®µå) ¿À´Ã °­¿¬¿¡¼­´Â ù°, ¾È±¸ Ç¥¸é¿¡ Á¡ÀûÇÏ´Â º¸Á¸Á¦°¡ ÇÔÀ¯µÈ Á¡¾ÈÁ¦ »ç¿ëÀÇ Á߿伺°ú µÑ°, ´«²¨Ç® Ä¡·á¿¡ ´ëÇØ »ìÆ캸°Ú
¸ÞµðÄ®·³   2015-01-05
[ÇмúÇà»ç] °üÀý¿° Ä¡·áÀÇ ÃÖ½ÅÁö°ß Àü¹®°¡Æ÷·³
ÅðÇ༺ ¿äÃߺ¯Çü ±³Á¤¿¡¼­ Àü¹æ¼ö¼úÀÇ ¿ªÇÒÅðÇ༺ ¿äÃߺ¯ÇüÀÇ ¼ö¼úÄ¡·á´Â ´ë°³ ALIF(anterior lumbar interbody fusion)¿Í ÈĹæôÃ߰泪»ç¸ø°íÁ¤¼ú(posterior pedicle screw fixation)À» ÅëÇØ ÀÌ·ç¾îÁø´Ù. ÅðÇà
¸ÞµðÄ®·³   2014-12-03
 1 | 2 
ÁÖ°£ Àαâ±â»ç
¿©¹é
¿©¹é
½Å¹®»ç¼Ò°³¤ý±â»çÁ¦º¸¤ý±¤°í¾È³»¤ýºÒÆí½Å°í¤ý°³ÀÎÁ¤º¸Ãë±Þ¹æħ¤ýÀ̸ÞÀϹ«´Ü¼öÁý°ÅºÎ¤ýû¼Ò³âº¸È£Á¤Ã¥¤ýȸ»ç À¥¸ÞÀÏ
¼­¿ï½Ã ¿ë»ê±¸ ÇÑ°­´ë·Î 39±æ 34-5, 805È£(ÇÑ°­·Î2°¡, ¸®¹öÆÄÅ©)  |  ´ëÇ¥ÀüÈ­ : 02-749-0322  |  Æѽº : 02-749-0323
(ÁÖ)¸ÞµðÄ®·³  |  µî·Ï¹øÈ£ : ¼­¿ï ¾Æ 02869  |  µî·ÏÀÏ : 2013³â 11¿ù 08ÀÏ  |  ¹ßÇàÀΡ¤ÆíÁýÀÎ : ±èÇö¹Î  |  Ã»¼Ò³âº¸È£Ã¥ÀÓÀÚ : ±èÇö¹Î
±¤°í¹®ÀÇ : TEL. 02-749-0322   FAX. 02-749-0323   E-mail. webmaster@medicolumn.com
Copyright © 2013 ¸ÞµðÄ®·³. All rights reserved.